Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results were achieved irrespective of GLP-1 duration, GLP-1 type, or insulin therapy type FreeStyle Libre systems help people adhere to diabetes treatment plans and support positive behavior changes by providing real-time data that shows how food, activity and medication can impact a person's glucose levels ABBOTT PARK, Ill., March 6, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new data from two real-world studies1, 2 showing people with Type 2 diabetes using GLP-1 medicines and FreeStyle Libre technology together had greater improvement in their HbA1c when compared to those treated with GLP-1 medicines only.

Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

In the most recent trading session, Abbott (ABT) closed at $118.48, indicating a -1.3% shift from the previous trading day.

Why Abbott (ABT) Dipped More Than Broader Market Today

Abbott's most important franchise works well in combination with weight-loss treatments. The company is also looking to address another problem these medicines create.

Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite

Johnson & Johnson

UnitedHealth Group

UnitedHealth is a central cog in U.S. healthcare. Johnson & Johnson is arguably the world's most financially secure company.

Nearing Retirement? These Stocks Are as Cautious as They Come

ABT continues to ride the diabetes tailwinds, as the market turns increasingly optimistic about the synergistic use of CGM and Ozempic/Mounjaro for overall patient care.

Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024

AbbVie

UnitedHealth Group's dividend yield isn't huge, but it's raising the payout rapidly. AbbVie's dividend is in a slump, but it offers an above-average yield now and could start soaring in a couple of years.

3 Magnificent Dividend Growth Stocks to Buy Now and Hold for at Least a Decade

Conagra Brands

Pfizer

In the stock market, finding solid blue-chip stocks can lead to substantial portfolio growth. While the hype of flashy stocks often gets headlines, the steady performers driving constant returns truly boost portfolios.

3 Blue-Chip Stocks to Buy to Bolster Your Portfolio

Abbott has delivered share price performance and passive income to investors for years. The company is diversified across healthcare businesses and sells many leading products.

Could Abbott Laboratories Stock Help You Become a Millionaire?

Abbott (ABT) reported earnings 30 days ago. What's next for the stock?

Abbott (ABT) Up 5.8% Since Last Earnings Report: Can It Continue?

International Seaways

Kroger

Procter & Gamble

Restaurant Brands

Investors in the vulnerable global economy constantly seek the Holy Grail: stocks immune to economic downturns. As the stock markets sway with economic and geopolitical uncertainty winds, finding those rare diamonds can feel like navigating a labyrinth blindfolded.

Recession-Proof Riches: 7 Stocks to Buy for Bulletproof Portfolio Growth

Abbott (NYSE: ABT) reported its Q4 results last month, with revenues above and earnings aligning with the street estimates. The company reported revenue of $10.24 billion and earnings of $1.19 on a per-share and adjusted basis, compared to the consensus estimates of $10.19 billion and $1.19, respectively.

What's Next For Abbott Stock After A 6% Rise This Year?

FedEx

Honeywell

Humana

Coca-Cola

Humana announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 26, 2024 to stockholders of record as of the close of business on March 29, 2024.

Daily Dividend Report: Humana, Fedex, Honeywell, Coca-Cola, Abbott

ABBOTT PARK, Ill., Feb. 16, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share.

Abbott Declares 401st Consecutive Quarterly Dividend

Advisers to the U.S. Food and Drug Administration on Tuesday backed an approval for Abbott Laboratories' heart valve repair device that is designed for patients who are at risk of complications or death during surgery.

Abbott's heart valve repair device gets FDA advisers' backing

Abbott Laboratories ABT, -1.06% said that a Food and Drug Administration panel voted in favor of the safety profile of its heart device TriClip.

Abbott Laboratories says FDA independent panel votes to approve heart device

Panel of independent experts reviewed data from the TRILUMINATE™ pivotal trial demonstrating safety, effectiveness and quality-of-life benefits of the TriClip system An investigational device in the U.S., TriClip is approved in more than 50 countries and has treated more than 10,000 people with tricuspid regurgitation worldwide ABBOTT PARK, Ill., Feb. 13, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the U.S. Food and Drug Administration (FDA) confirmed 13 to 1, with 0 abstention that the benefits of Abbott's TriClip™ transcatheter edge-to-edge repair (TEER) system outweighed the risks for the treatment of people with tricuspid regurgitation (TR).

FDA Advisory Committee Votes in Favor of Abbott's First-of-Its-Kind TriClip™ System to Treat People With a Leaky Tricuspid Heart Valve

Diabetes and obesity treatments including Ozempic, Wegovy, and Mounjaro are experiencing extraordinary demand. One unintended consequence of losing weight can be shedding muscle mass, which can be detrimental to overall health.

Abbott Laboratories Is the Latest Company to Get Involved in the Weight Loss Market. Here's How.

CRISPR Therapeutics

Vertex Pharmaceuticals

The health sector has two things to offer: new ideas and consistent returns. As a result, healthcare stocks will continue to be a good choice for investors looking for growth opportunities in 2024.

3 Groundbreaking Healthcare Stocks to Buy for Robust Gains

Allianz SE

Advanced Micro Devices

Ares Capital

Broadcom

British American Tobacco

Chevron

Enterprise Products Partners

Home Depot

iShares Core MSCI Europe ETF

McDonald's

Altria

NextEra Energy

NVIDIA

Realty Income Corp

PepsiCo

Schwab US Dividend Equity ETF

SPDR S&P 500 ETF Trust

AT&T

Taiwan Semiconductor Manufacturing

Texas Instruments

Reaching retirement and having enough capital to build a dividend money machine are dreams shared by many. With life expectancy on the rise, high yield alone is no longer sufficient; we need to plan for both capital appreciation and dividend growth.

How I Would Invest $1,000,000 And Live Of Dividends Forever

The U.S. Food and Drug Administration (FDA) staff reviewers did not raise any new concerns on Friday over the safety and effectiveness of Abbott's heart valve repair device designed for patients who are at risk for surgery.

US FDA staff raises no new concerns about Abbott's heart device

Regeneron Pharmaceuticals

Abbott Laboratories and Regeneron are looking to solve a problem Ozempic may exacerbate. Both could benefit from the substantial increase in popularity of meds like Ozempic as a result.

These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?

Costco

Franklin Electric

Microsoft

Oshkosh

One mistake investors make when buying dividend stocks is chasing yield. Stocks with the highest yield could be a sign a company is struggling, which could put the yield at risk.

7 Tremendous Dividend Stocks With Double-Digit 5-Year Growth Rates

Pfizer's regrouping at the moment, but it is poised to shine again. UnitedHealth Group is a healthcare juggernaut with more success ahead.

Want to Get Richer? Here Are the 3 Best Stocks to Buy Now and Hold Forever

Netflix

Abbott Laboratories didn't perform well last year, but it still has bright prospects. Netflix reported strong earnings that point to plenty of growth potential ahead.

2 Stocks to Buy Near Their 52-Week Highs

Abbott Laboratories and Johnson & Johnson have increased their payouts annually for 52 and 61 consecutive years, respectively. Both healthcare companies have long track records of important innovations and strong financial performances.

News for Abbott Labs Stock (ABT)